This article was originally published here
Front Oncol. 2021 Feb 5;10:1731. doi: 10.3389/fonc.2020.01731. eCollection 2020.
ABSTRACT
PURPOSE: Paclitaxel liposome (Lipusu) is the first commercialized liposomal formulation of paclitaxel. There has been little data collected on the pharmacokinetics (PK) of paclitaxel liposome, especially in relation to patient use. This study aimed to build a population pharmacokinetic (PopPK) model and further explore the exposure-safety relationship for paclitaxel liposome in patients with non-small cell lung cancer (NSCLC).
METHODS: Data from 45 patients with a total of 349 plasma concentrations were analyzed. The PopPK model was built using the non-linear mixed effect modeling technique.
RESULTS: The PK of paclitaxel liposome were well described by a three-compartment model with first-order elimination. For a dose of 175 mg m-2, the estimated clearance of total plasma paclitaxel was 21.55 L h-1. Age, sex, body weight, total bilirubin, albumin, serum creatinine, and creatinine clearance did not influence the paclitaxel PK. Exposure to paclitaxel had no significant change in the presence of the traditional Chinese medicine, aidi injection. The exploratory exposure-safety relationship was well described by a generalized linear regression model. Higher probabilities of grade >1 neutropenia were observed in patients with higher exposure to paclitaxel.
CONCLUSION: This PopPK model adequately described the PK of paclitaxel liposome in patients with NSCLC. Predicted exposure of paclitaxel did not change in the presence of the traditional Chinese medicine, aidi injection. The exposure-safety analysis suggested that a higher risk of neutropenia was correlated with higher exposure to paclitaxel.
PMID:33614470 | PMC:PMC7892953 | DOI:10.3389/fonc.2020.01731
